2023 Fall Conference | Industry Therapeutic Update from Eisai: An Option for Intervention in Early Alzheimer’s Disease: MCI Due to AD or Mild AD Dementia

Date Friday 10/27/23

Time 05:45 PM - 06:45 PM PDT Add To Calendar

Session Format This program will be presented in-person only

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Director(s) Justin S. Moon, MD

Topic(s) Aging and Dementia, Aging, Dementia, and Behavioral Neurology

Learning Objectives Review the Prescribing Information for LEQEMBI (lecanemab-irmb) for the treatment of MCI due to AD and mild AD dementia and highlight key considerations for clinical practice, including:

Identifying appropriate patients for treatment with LEQEMBI
Key efficacy and safety data from the Clarity AD study Important safety information, including boxed warning for ARIA
Best practices for screening and management of ARIA
Navigating the steps from diagnosis to treatment with LEQEMBI.

Please note that no CME will be given by any accredited organization for attending. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2023 AAN Fall Conference education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

CME Available No CME available

Program Materials

Event Timeline
05:45 PM - 06:45 PM PDT	Speaker	Industry Therapeutic Update from Eisai: An Option for Intervention in Early Alzheimer’s Disease: MCI Due to AD or Mild AD Dementia

Faculty Disclosures
Justin S. Moon, MD	The institution of Dr. Moon has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Eisai. The institution of Dr. Moon has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbvie. Dr. Moon has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. The institution of Dr. Moon has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CSL Behring. The institution of Dr. Moon has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Eisai. Dr. Moon has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Abbvie. Dr. Moon has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Averitas. Dr. Moon has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant with Copic .

��ɫ��

��ɫ��